Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects

NCT02509845 | Completed Phase 2

• 1 other identifier: C3J15-202-00
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 5

Brief Summary

The purpose of the clinical study is to evaluate the safety and bacterial impact of study drug (C16G2) administered in multiple oral gel doses to adolescent and adult dental subjects.

Conditions

Dental Caries

Outcome Measures

Primary Outcomes (1)

• Safety of multiple C16G2 Gel administrations as measured by adverse events

  Subjects will be monitored for adverse events throughout the study. At specified clinic visits a targeted physical exam and oral cavity assessment will be performed and vital signs will be taken.

  Screening to week 41

Secondary Outcomes (2)

• Targeted antimicrobial activity of C16G2 Gel applications as measured by a reduction in Streptococcus mutans in saliva and dental plaque

  Microbiology assessments at screeninig, weeks 1, 2, 4, 8, 12, 13, 27, and 41

• Total bacteria in saliva and dental plaque post-study drug administration

  Total bacteria at weeks 1, 2, 13, 14

Study Arms (3)

Adolescent Safety Only Cohort

EXPERIMENTAL

Prior to commencing enrollment of subjects 12-17 years of age in Study Arms 1 \& 2, a safety only cohort of 4 to 8 adolescent subjects will receive 4 administrations of C16G2 on Day 0.

Drug: C16G2; Other: Placebo

Study Arm 1

EXPERIMENTAL

Subjects will receive 2 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 1 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.

Drug: C16G2; Other: Placebo

Study Arm 2

EXPERIMENTAL

Subjects will receive 4 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 2 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.

Drug: C16G2; Other: Placebo

Interventions

C16G2 DRUG

Antimicrobial peptide

Also known as: Antimicrobial peptide

Adolescent Safety Only Cohort; Study Arm 1; Study Arm 2

Placebo OTHER

Placebo

Adolescent Safety Only Cohort; Study Arm 1; Study Arm 2

Eligibility Criteria

• Age: 12 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Adolescent Safety Only Cohort: Males and females, 12-17 years of age, inclusive, at the time the Assent and Informed Consent Form is signed. Study Arms 1 \& 2: Males and females, 12-75 years of age, inclusive, at the time the Assent and/or Informed Consent Form is signed
• Female subjects of childbearing potential, defined as not surgically sterile or at least two (2) years postmenopausal, must agree to use one of the following forms of contraception from screening through the last study visit: hormonal (oral, implant, or injection) begun \>30 days prior to screening; barrier (condom, diaphragm, or cervical cap with spermicide); intrauterine device (IUD). Acceptable contraceptive options may also include abstinence, relationship with same sex partner or partner who has had a vasectomy at least six (6) months prior to the screening visit
• Male subjects only: willing to use contraception or abstain from sexual activity beginning with the first exposure to study drug and continuing until discharged from the study due to completion or Early Termination
• Healthy, as determined by the Investigator, based on medical and dental history, concurrent illnesses, laboratory results, concomitant medications, oral cavity assessment, and targeted physical examination (extraoral, head and neck) during Screening
• Have a minimum of six unrestored bicuspids and molars with ≤50% of molars and bicuspids having restorations, crowns, sealants or are missing
• Demonstrated ability to expectorate ≥2mL of stimulated saliva in 5 minutes
• Have a salivary S. mutans of 1.0 x 10e5 CFUs/mL or greater at Screening using MSB agar plating
• Willing to refrain from using non-study dentifrice and other non-study oral care products (oral care rinses, fluoride products, etc.) during the study
• Willing to postpone elective dental procedures (e.g., dental cleanings) between Screening and final post-treatment visit
• Willing and able to comply with oral hygiene and diet instructions
• Has dentition adequate for custom dental tray gel application
• Able to understand and sign the Assent and/or Informed Consent Form prior to initiation of study procedures
• Able to communicate with the Investigator/study center personnel, understand and comply with the study requirements, and willing to return for protocol-specified visits at the appointed times

You may not qualify if:

• Advanced periodontal disease
• Active caries lesion(s) within 30 days prior to study drug administration (confirmed by comprehensive caries examination including standard radiographs); Note: Subjects presenting with insipient, non-cavitated lesion(s) are not excluded
• Medical condition (e.g., artificial heart valve, history of infective endocarditis, cardiac transplant with valvular dysfunction, congenital heart disease or total joint replacement) for which antibiotics are recommended prior to dental visits and/or procedures
• Pathologic lesions of the oral cavity
• Full or partial dentures, or orthodontic appliances, e.g., night guards, permanent retainers
• Use of systemic antibiotics, topical oral antibiotics, or use of other drugs, which in the opinion of the Investigator could influence the study outcome, within 30 days prior to Screening
• Medical history indicating the woman is pregnant, breastfeeding/ lactating or has a positive urine pregnancy test
• Participation in a clinical trial or receipt of a non-FDA approved therapy within 30 days prior to study drug administration
• Prior participation in a C16G2 clinical trial and known to have received C16G2 active gel or mouth rinse
• Presence of any condition or concurrent illness, which in the opinion of the Investigator, would compromise normal immune function, interfere with the use of study dentifrice and oral care products, or interfere with the ability to comply with study requirements, or jeopardize the safety of the subject or the validity of the study results

Sponsors & Collaborators

• Armata Pharmaceuticals, Inc.: lead

Study Sites (5)

Indiana University School of Dentistry

Indianapolis, Indiana, 46202, United States

Location

John F. Pittaway, DMD

Kalispell, Montana, 59901, United States

Location

New York University College of Dentistry

New York, New York, 10010, United States

Location

University of Pennsylvania School of Dental Medicine

Philadelphia, Pennsylvania, 19104, United States

Location

Anthony Henegar, DDS, PA

Irving, Texas, 75063, United States

Location

MeSH Terms

Conditions

Dental Caries

Interventions

Antimicrobial Peptides

Condition Hierarchy (Ancestors)

Tooth Demineralization; Tooth Diseases; Stomatognathic Diseases

Intervention Hierarchy (Ancestors)

Peptides; Amino Acids, Peptides, and Proteins

Study Officials

• Mark Wolff, MD

  New York University, School of Dentistry

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 1, 2015
• First Posted: July 28, 2015
• Study Start: July 1, 2015
• Primary Completion: February 1, 2016
• Study Completion: March 1, 2016
• Last Updated: August 1, 2019

Record last verified: 2019-07

Locations

US (5)